Gilead Sciences - GILD Stock Forecast, Price & News

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View GILD analyst ratings or view top-rated stocks.

14 Wall Street research analysts have issued 12 month price targets for Gilead Sciences' stock. Their GILD share price forecasts range from $56.00 to $90.00. On average, they expect the company's stock price to reach $72.40 in the next year. This suggests a possible upside of 11.2% from the stock's current price.
View analysts price targets for GILD or view top-rated stocks among Wall Street analysts.

Gilead Sciences' stock was trading at $72.61 at the beginning of 2022. Since then, GILD stock has decreased by 10.4% and is now trading at $65.09.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our GILD earnings forecast.

Gilead Sciences, Inc. (NASDAQ:GILD) released its earnings results on Thursday, October, 28th. The biopharmaceutical company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.93. The biopharmaceutical company earned $7.42 billion during the quarter, compared to the consensus estimate of $6.31 billion. Gilead Sciences had a trailing twelve-month return on equity of 42.92% and a net margin of 15.03%. The firm's revenue was up 12.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.11 earnings per share.
Read the conference call transcript.

Gilead Sciences declared a quarterly dividend on Tuesday, August 2nd. Shareholders of record on Thursday, September 15th will be paid a dividend of $0.73 per share on Thursday, September 29th. This represents a $2.92 dividend on an annualized basis and a yield of 4.49%. The ex-dividend date is Wednesday, September 14th.
Read our dividend analysis for GILD.

Gilead Sciences (NASDAQ:GILD) pays an annual dividend of $2.92 per share and currently has a dividend yield of 4.40%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 89.02%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, GILD will have a dividend payout ratio of 46.06% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GILD.

Gilead Sciences updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of $6.35-$6.75 for the period, compared to the consensus estimate of $6.57. The company issued revenue guidance of $24.50 billion-$25.00 billion, compared to the consensus revenue estimate of $24.57 billion.

107 employees have rated Gilead Sciences Chief Executive Officer Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among the company's employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Gilead Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (4.62%), Dodge & Cox (2.95%), Northern Trust Corp (1.22%), Renaissance Technologies LLC (1.07%), Parnassus Investments LLC (0.93%) and UBS Asset Management Americas Inc. (0.74%). Insiders that own company stock include Brett A Pletcher, Diane E Wilfong, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, Johanna Mercier, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends.

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GILD stock can currently be purchased for approximately $65.09.

Gilead Sciences (NASDAQ:GILD) has a market capitalization of $81.58 billion and generates $27.31 billion in revenue each year. The biopharmaceutical company earns $6.23 billion in net income (profit) each year or $3.28 on an earnings per share basis.

The company employs 14,400 workers across the globe.

Gilead Sciences was founded in 1987.

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The official website for the company is www.gilead.com. The biopharmaceutical company can be reached via phone at (650) 574-3000, via email at investor_relations@gilead.com, or via fax at 650-578-9264.